Vivli Launches a Public Beta Version of Its Innovative Data-Sharing Platform

Vivli’s powerful search engine allows users to preview search
functionality prior to launch in July

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vivli opened up the beta version of its novel global platform for
sharing clinical trials today. Researchers and others users can go to app.vivli.org,
try out the search functionality and provide feedback to Vivli about
enhancements they would like to see before the formal launch in July.

During the beta test period, the public will have access to the search
tool on the platform, and while the process to request data and other
functionality will be rolled out with the full release at launch, users
can provide valuable feedback to the development team on the core search
functionality and interface of the platform. Vivli’s full launch is
scheduled for July 19, 2018, at the National Academy of Sciences in
Washington, D.C.

“Vivli’s intuitive search interface allows users to refine their search
and only request the studies that they need to answer important research
questions,” said Dr. Ida Sim, Vivli’s Technical Lead. “This will
hopefully accelerate the research process to drive forward scientific
discovery.”

Vivli will offer the research community the opportunity to store,
request and analyze anonymized clinical trial data in a secure research
environment, with built in protections for data security and privacy.

Vivli is grateful to the support of the following organizations for
supporting the development of the Vivli platform and allowing the
studies associated with their organizations to be included in the public
beta test of the search function. These leaders in data sharing and
transparency include: Critical Path Institute, GlaxoSmithKline, ImmPort
(a data-sharing platform funded by the National Institutes of Health),
Johnson & Johnson, Pfizer, Project Data Sphere LLC, and Takeda.

“Critical Path Institute (C-Path) is pleased to participate in the Vivli
Beta project. C-Path is committed to supporting efforts such as this to
leverage and share as much information as possible to more fully
understand disease characteristics, and ultimately benefit those living
with disease,” Martha Brumfield, Critical Path Institute CEO.

“We believe that data transparency can promote scientific innovation and
ultimately improve patient care,” said Kate Knobil, GSK’s Chief Medical
Officer. “We continue to collaborate in the quest for the best ways to
increase access to this vital information. That’s one reason we are
contributing studies to the beta test of the Vivli search function while
continuing to support the Clinical
Study Data Request
online site, where we make more than 2,000 of our
studies available for data sharing.”

“Johnson & Johnson believes in the importance of data sharing, as is
evidenced through our continued engagement with the YODA
Project
. We believe that the goal of data sharing—advancing science
and medicine for the benefit of patients–will only fully be realized
when all stakeholders who generate clinical data participate. We hope
that new platforms, such as that being created by Vivli, will lead to a
broadening of engagement by other stakeholders in the R&D ecosystem,”
said Joanne Waldstreicher, M.D., Chief Medical Officer, Johnson &
Johnson.

“Pfizer has had a longstanding commitment to ensure that data are
available to those who need them, including researchers, trial
participants, regulators, and others acting in the best interest of
patients,” said Freda Lewis-Hall, M.D., Executive Vice President and
Chief Medical Officer, Pfizer. “We are proud to have participated in the
development of the Vivli platform and look forward to learnings from the
beta testing period, to help demonstrate how Vivli’s approach may
promote effective and ethical collaborations, build trust throughout the
health care system, and enable monitoring of the progress being made to
address unmet medical needs.”

“Giving researchers the ability to easily find clinical trial
patient-level data spread across different data sharing platforms will
enable them to more comprehensively investigate how to improve patient
outcomes,” said Bill Louv, President for Project Data Sphere, LLC. “In
working with Vivli and the other stakeholders, we’re excited to be
extending the value of the cancer trial data we continue to aggregate.”

“Takeda is strongly committed to our core value of integrity and an
important way to demonstrate this commitment is through maximizing the
transparency of our clinical research,” said Patrick Cullinan, Head of
Clinical Transparency at Takeda Pharmaceuticals. “As such, Takeda has
been a leader in the field of patient-level data sharing and has been
proud to support the development of the Vivli platform from its
inception through the current beta testing. Takeda sees enormous
potential in Vivli’s vision to create a more connected and interoperable
data sharing research environment to facilitate additional innovative
science that maximizes use of existing clinical trial data. Takeda
believe this responsible reuse of our patient’s data further honors and
respects trial participant’s contribution to research, while also
supporting the research community by facilitating discovery and
responsible access to data.”

About Vivli

Vivli is a non-profit organization that is establishing a global
data-sharing and analytics platform to serve all elements of the
international research community. We act as a neutral broker between
data contributor and data user and the wider data sharing community.
Vivli is establishing an independent data repository, in-depth search
engine and a cloud-based analytics platform. We are working to provide
the platform as well as harmonize the governance, policy and processes
to make sharing data easier. The ultimate aim of Vivli is to advance
human health from the insights and discoveries gained by sharing and
analyzing clinical research data.

Contacts

Vivli
Julie Wood, 1 573-514-3305
jwood@vivli.org
or
GlaxoSmithKline
Mary
A. Rhyne

Mobile: 919-412-9089
mary.a.rhyne@gsk.com
or
Johnson
& Johnson

Kim Fox
Mobile: 862-212-2409
KFox13@its.jnj.com